ORIMEDA - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 305,081 | 266,487 | 209,688 | 237,460 | 240,074 | 243,853 | 250,353 | 219,993 |
| Profit before tax | 16,191 | 431 | 13,332 | 32,899 | 646 | 6,250 | 6,507 | 15,907 |
| Net profit | 14,514 | -26 | 12,606 | 31,185 | 422 | 5,701 | 5,058 | 15,043 |
| Equity | 88,956 | 88,930 | 101,536 | 132,721 | 103,143 | 108,844 | 113,902 | 128,945 |
| Liabilities | 39,743 | 32,420 | 34,567 | 39,442 | 72,972 | 72,174 | 61,288 | 35,661 |
| Non-current assets | 12,409 | 9,372 | 6,965 | 4,594 | 4,133 | 2,094 | 512 | 342 |
| Current assets | 115,827 | 111,492 | 127,708 | 167,262 | 171,530 | 178,728 | 174,466 | 164,193 |
| Total assets | 128,236 | 120,864 | 134,673 | 171,856 | 175,663 | 180,822 | 174,978 | 164,535 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 53,725 | 63,292 | 55,424 |
| Social insurance contributions | - | - | - | - | - | - | - | 5,756 |
|
Financial indicators
|
||||||||
| Revenue change y/y | -5.9% | -12.7% | -21.3% | +13.2% | +1.1% | +1.6% | +2.7% | -12.1% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 11.3% | 0.0% | 9.4% | 18.1% | 0.2% | 3.2% | 2.9% | 9.1% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 16.3% | 0.0% | 12.4% | 23.5% | 0.4% | 5.2% | 4.4% | 11.7% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 4.8% | 0.0% | 6.0% | 13.1% | 0.2% | 2.3% | 2.0% | 6.8% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 5.3% | 0.2% | 6.4% | 13.9% | 0.3% | 2.6% | 2.6% | 7.2% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.4 | 0.4 | 0.3 | 0.3 | 0.7 | 0.7 | 0.5 | 0.3 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 101,694 | 76,139 | 58,518 | 89,046 | 120,037 | 121,927 | 100,141 | 62,855 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
ORIMEDA - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-02-18 | 2026-02-25 | 6.34 |
ORIMEDA - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
ORIMEDA, UAB (code 300994589) is a Private Limited Liability Company engaged in the wholesale of pharmaceutical and medical goods. In the latest financial year, 2025, the company generated revenue of €220.0K and net profit of €15.0K, corresponding to a profit margin of 6.8%. Revenue declined by 12.1% year on year in 2025 and was 9.8% lower than two years earlier, but profitability strengthened materially. Net profit increased from €5.7K in 2023 to €5.1K in 2024 and then rose to €15.0K in 2025, showing a clear improvement in earnings quality despite the lower turnover. The balance sheet remained solid: total assets were €164.5K, equity €128.9K and liabilities €35.7K at the end of 2025. The equity ratio was 78.4% and debt-to-equity stood at 0.28, indicating moderate leverage. Asset turnover reached 1.34x, while ROE was 11.7% and ROA 9.1%. Revenue per employee was €73.3K, with profit per employee at €5.0K, pointing to steady operational productivity.